BioStock: PHIs CEO eyes new business opportunities

March 31, 2022
Language flag

In 2021, PHI entered into a partnership with the US-based RegenMed Development Organization with the goal of establishing the company’s HoloMonitor technology as the standard quality control equipment in the growing field of regenerative medicine. The company has also chartered a new course when it comes to marketing strategy, with a sharp increase in sales over the last 4 quarters as a result. BioStock contacted CEO Peter Egelberg to find out more about the rights issue of just over 72 million SEK that is currently underway, and his vision for the future.

Read the full interview with Peter Egelberg on biostock.se.

Latest News

Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB 2 December 2024

Phase Holographic Imaging PHI AB (publ), 556542-7811 (the “Company”) will hold an Extraordinary General Meeting on 2 December 2024 at 15.00 CET at the Company’s premises, Skiffervägen 48 in Lund.

PHI resolves on a fully secured rights issue of shares of approximately SEK 64.3 million

The Board of Directors of Phase Holographic Imaging PHI AB has today resolved on a rights issue of shares, with preferential rights for the Company’s existing shareholders, of approximately SEK 64.3 million before deduction of issue related costs, subject to approval by the extraordinary general meeting to be held on 2 December 2024. The purpose of the Rights Issue is to fund a strategic development plan and to strengthen the Company’s capital structure by repayment/off-setting of outstanding loans.

Adopting the final Annual Report

PHI intends to convene a general meeting to adopt the annual report for the fiscal year 2023/2024 and to amend resolutions regarding election of board members and the number of board members.
See All News